COVID-19 Pfizer Information
Underserved Patient Populations We can Do More
Symposia Trailer Video
The Role of Cyclin-Dependent Kinases (CDK) 2/4/6 in Normal and Tumor Cells
ABC Global Alliance
Hard-to-Reach ABC/mBC Communities Toolkit
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
IBRANCE® (palbociclib) Product Information
IBRANCE® (palbociclib) German SmPC
IBRANCE® (palbociclib) English SmPC
TALZENNA® (talazoparib) German SmPC
TALZENNA® (talazoparib) Product Information
TALZENNA® (talazoparib) English SmPC
TRAZIMERA® (trastuzumab) Product Information
TRAZIMERA® (trastuzumab) German SmPC
TRAZIMERA® (trastuzumab) English SmPC
Pfizers Sponsored Scientifc Presentations including Abstract Plain Language Summaries
The Value of RWE
Symposia Invite
Investigator Resources and How to Contact Us
Get It Done: Return to Cancer Screening Telehealth Guide for Patients- English Version
Get It Done: Return to Cancer Screening In-Person Guide for Patients- English Version
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
What to Expect With Your Cancer Care During COVID-19
Broadening horizons in HER2 - advanced breast cancer
Follow Us on Twitter @PfizerOncMed
Discover the Oncology Development Program and Clinical Trials
Pfizer Medical Information
Improving Access to Care for Underserved Patient Populations
Age: Addressing a Blind Spot in Cancer Care
Clinical Trial Resources
Breast Cancer Vision
This is Living with Cancer
Abstract Plain Language Summaries
Thanks for finding us at ESMO Breast 2022
Who We Are and What We Do
Over the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer. Now, we’re working tirelessly to develop a new generation of breakthroughs across multiple cancers and tumor types.
Thank you for finding us at ESMO Breast 2023
Who We Are and What We Do
One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases
Opportunities To Connect
Upcoming Opportunities
to Connect
Upcoming Opportunities to Connect
Symposia
Poster Presentations
A team member will respond to your inquiry.
Learn About Our Oncology Approved Medicines
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
